Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), announced today that XPOVIO®(selinexor) has been granted approval from the Health Sciences Authority (HSA) in Singapore for three indications.
| SHANGHAI and HONG KONG, March 1, 2022 /PRNewswire/ -- Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening diseases, announced today that XPOVIO®(selinexor) has been granted approval from the Health Sciences Authority (HSA) in Singapore for three indications:
- Relapsed or refractory multiple myeloma (R/R MM) in combination with bortezomib and dexamethasone, for treatment of adult patients with R/R MM who have received at least one prior therapy Thomas Karalis, Head of APAC Markets commented: “Despite recent advances in the treatment of R/R MM and R/R DLBCL, there remains a continuing unmet need to extend survival for patients with these life-threatening diseases. The approval of XPOVIO® presents Singapore physicians and patients with a novel addition to their existing regimens in their treatment of R/R MM and R/R DLBCL and we are very pleased to be launching XPOVIO® in Singapore and across APAC markets in the coming months.” “I am very pleased for Antengene to receive clearance from HSA and to be able to bring XPOVIO®, the first and only XPO1 inhibitor, to patients in Singapore with R/R MM and R/R DLBCL,” said Dr. Jay Mei, Antengene’s Founder, Chairman and CEO. “Receiving regulatory clearance for three important indications at the same time enables Antengene to fulfill its mission to bring first-in-class/best-in-class medicines to patients with cancer and other life-threatening diseases in APAC markets and beyond.” Dr. Mei further commented: “Selinexor has been evaluated in more than 10 studies and widely adopted into practice guidelines by major oncology societies around the world. Over the last few years, we have been pleased to provide selinexor to 390 patients in Asia Pacific in an early access program. Now, our commercial team is well prepared to market the product in Singapore, building upon our commercialization experience with XPOVIO® launches in China and South Korea.” About the SINE Compounds SINE (Selective Inhibitor of Nuclear Export) compounds are inhibitors of the major nuclear export protein Exportin 1 (XPO1). Currently, there are three oral SINE compounds, ATG-010 (selinexor), ATG-016 (eltanexor), and ATG-527 (verdinexor), under clinical development. Antengene has an exclusive license from Karyopharm Therapeutics Inc. (“Karyopharm”) to these compounds in certain APAC markets. About XPOVIO®/ATG-010/Selinexor Selinexor is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration (FDA). By blocking the nuclear export protein XPO1, selinexor can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. This induces apoptosis without affecting normal cells. Due to its novel mechanism of action, selinexor is being evaluated for use in multiple combination regimens to improve treatment efficacy. Selinexor is approved by the US FDA for the treatment of R/R MM and R/R DLBCL. Antengene secured approval of selinexor in China in December 2021 for R/R MM and plans to launch the product in the second quarter of 2022. Antengene also secured approval for selinexor in South Korea for use in R/R MM and R/R DLBCL in July 2021 and in Singapore for use in R/R MM and R/R DLBCL in March 2022. Antengene is conducting 10 studies in mainland China (3 in collaboration with Karyopharm) for relapsed/refractory hematological malignancies and advanced solid tumors. About Antengene Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of “Treating Patients Beyond Borders”, Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 21 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for selinexor/ATG-010/XPOVIO® in China, South Korea and Singapore approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs. Forward-Looking Statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company’s Annual Report for year-end December 31, 2020, and subsequent filings with the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: PR Contacts:
SOURCE Antengene Corporation Limited | ||
Company Codes: HongKong:06996, HongKong:6996 |
View original content to download multimedia:
